RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer

BACKGROUND: Oestrogen Receptor 1 (ESR1) mutations are frequently acquired in oestrogen receptor (ER)-positive metastatic breast cancer (MBC) patients who were treated with aromatase inhibitors (AI) in the metastatic setting. Acquired ESR1 mutations are associated with poor prognosis and there is a l...

Descripción completa

Detalles Bibliográficos
Autores principales: Dustin, Derek, Gu, Guowei, Beyer, Amanda R., Herzog, Sarah K., Edwards, David G., Lin, Hangqing, Gonzalez, Thomas L., Grimm, Sandra L., Coarfa, Cristian, Chan, Doug W., Kim, Beom-Jun, De La O, Jean-Paul, Ellis, Matthew J., Liu, Dan, Li, Shunqiang, Welm, Alana L., Fuqua, Suzanne A. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782501/
https://www.ncbi.nlm.nih.gov/pubmed/33257837
http://dx.doi.org/10.1038/s41416-020-01174-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782501/
https://www.ncbi.nlm.nih.gov/pubmed/33257837
http://dx.doi.org/10.1038/s41416-020-01174-z

Ejemplares similares